Literature DB >> 30446337

PHA eludes macrophage suppression to activate CD8+ T cells.

Yelizavet D Lomakova1, Jennifer Londregan1, Jeffrey Maslanka1, Naomi Goldman1, John Somerville1, James E Riggs2.   

Abstract

Tumors may include a high proportion of immune modulatory cells and molecules that restrain the anti-cancer response. Activation of T cells to eliminate cancer cells within the immune-suppressive tumor microenvironment remains a challenge. We have shown that C57BL/6 J peritoneal cell culture models features of macrophage-dense tumors as TCR ligation fails to activate T cells unless IFNγ is neutralized or iNOS is inhibited. We tested other forms of T cell activation and found phytohemagglutinin (PHA) distinctive in the ability to markedly expand CD8 T cells in this model. IFNγ or iNOS inhibition was not necessary for this response. PHA triggered less IFNγ production and inhibitory PD-L1 expression than TCR ligation. Macrophages and CD44hi T cells bound PHA. Spleen T cell responses to PHA were markedly enhanced by the addition of peritoneal cells revealing that macrophages enhance T cell expansion. That PHA increases CD8 T cell responses within macrophage-dense culture suggests this mitogen might enhance anti-tumor immunity.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Macrophage; Phytohemagglutinin; Suppression; T cell

Mesh:

Substances:

Year:  2018        PMID: 30446337      PMCID: PMC6387856          DOI: 10.1016/j.imbio.2018.10.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  57 in total

1.  Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes.

Authors:  P C NOWELL
Journal:  Cancer Res       Date:  1960-05       Impact factor: 12.701

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

4.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

5.  Macrophage regulation of B cell proliferation.

Authors:  Naomi Goldman; Kornelija Valiuskyte; Jennifer Londregan; Adam Swider; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2017-02-21       Impact factor: 4.868

6.  Murine cell surface glycoproteins. Purification of the polymorphic Pgp-1 antigen and analysis of its expression on macrophages and other myeloid cells.

Authors:  E N Hughes; A Colombatti; J T August
Journal:  J Biol Chem       Date:  1983-01-25       Impact factor: 5.157

Review 7.  T Cell Dysfunction in Cancer.

Authors:  Daniela S Thommen; Ton N Schumacher
Journal:  Cancer Cell       Date:  2018-04-09       Impact factor: 31.743

8.  Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans.

Authors:  L E Harrington; M Galvan; L G Baum; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

Review 9.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.

Authors:  Jiabei He; Ying Hu; Mingming Hu; Baolan Li
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

10.  Phaseolus vulgaris phytohaemagglutinin (PHA) binds to the human T lymphocyte antigen receptor.

Authors:  O P Chilson; A W Boylston; M J Crumpton
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

View more
  3 in total

1.  IgD ligation allows peritoneal cavity B cell proliferation.

Authors:  Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2022-01-20       Impact factor: 3.144

2.  Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.

Authors:  Kamonlapat Supimon; Thanich Sangsuwannukul; Jatuporn Sujjitjoon; Nattaporn Phanthaphol; Thaweesak Chieochansin; Naravat Poungvarin; Sopit Wongkham; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

3.  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.

Authors:  Maria V Konopleva; Vera N Borisova; Maria V Sokolova; Tatyana A Semenenko; Anatoly P Suslov
Journal:  Vaccines (Basel)       Date:  2022-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.